Skip to main content
SpringerLink
Log in

Treatment of Endometrial Cancer

  • Chapter
Gynecologic Cancer

Part of the book series: M. D. Anderson Cancer Care Series ((MDCCS,volume 5))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Readings

  • Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56:419–427.

    CAS  PubMed  Google Scholar 

  • Ayhan A, Taskiran C, Celik C, Aksu T, Yuce K. Surgical stage III endometrial cancer: analysis of treatment outcomes, prognostic factors and failure patterns. Eur J Gynaecol Oncol 2002;23:553–556.

    CAS  PubMed  Google Scholar 

  • Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1996;62:278–281.

    Article  CAS  PubMed  Google Scholar 

  • Bancher-Todesca D, Neunteufel W, Williams KE, et al. Influence of postoperative treatment on survival in patients with uterine papillary serous carcinoma. Gynecol Oncol 1998;71:344–347.

    CAS  PubMed  Google Scholar 

  • Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209–262.

    CAS  PubMed  Google Scholar 

  • Ben-Shachar I, Pavelka J, Cohn DE, et al. Surgical staging for patients presenting with grade 1 endometrial carcinoma. Obstet Gynecol 2005;105:487–493.

    PubMed  Google Scholar 

  • Brown JJ, Thurnher S, Hricak H. MR imaging of the uterus: low-signal-intensity abnormalities of the endometrium and endometrial cavity. Magn Reson Imaging 1990;8:309–313.

    CAS  PubMed  Google Scholar 

  • Burke TW, Gershenson DM, Morris M, et al. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma. Gynecol Oncol 1994;55:47–50.

    Article  CAS  PubMed  Google Scholar 

  • Corn BW, Lanciano RM, Greven KM, et al. Impact of improved irradiation technique, age, and lymph node sampling on the severe complication rate of surgically staged endometrial cancer patients: a multivariate analysis. J Clin Oncol 1994;12:510–515.

    CAS  PubMed  Google Scholar 

  • Covens A, Thomas G, Shaw P, et al. A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol Oncol 1997;64:126–129.

    Article  CAS  PubMed  Google Scholar 

  • Creasman WT, DiSaia PJ, Blessing J, Wilkinson RH Jr, Johnston W, Weed JC Jr. Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals. Am J Obstet Gynecol 1981;141:921–929.

    CAS  PubMed  Google Scholar 

  • Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326–330.

    CAS  PubMed  Google Scholar 

  • Creutzberg CL. GOG-99: ending the controversy regarding pelvic radiotherapy for endometrial carcinoma? [comment]. Gynecol Oncol 2004;92:740–743.

    PubMed  Google Scholar 

  • Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet 2000;355:1404–1411.

    Article  CAS  PubMed  Google Scholar 

  • Faquin WC, Fitzgerald JT, Lin MC, Boynton KA, Muto MG, Mutter GL. Sporadic MSI is specific to neoplastic and preneoplastic endometrial tissues. Am J Clin Pathol 2000;113:576–582.

    CAS  PubMed  Google Scholar 

  • Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S. ß-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998;58:3526–3528.

    CAS  PubMed  Google Scholar 

  • Gal D, Recio FO, Zamurovic D. The new International Federation of Gynecology and Obstetrics surgical staging and survival rates in early endometrial carcinoma. Cancer 1992;69:200–202.

    CAS  PubMed  Google Scholar 

  • Goff BA, Goodman A, Muntz HG, et al. Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol 1994;52:237–240.

    Article  CAS  PubMed  Google Scholar 

  • Goff BA, Kato D, Schmidt RA, et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994;54:264–268.

    Article  CAS  PubMed  Google Scholar 

  • Greven KM, Lanciano RM, Corn B, Case D, Randall ME. Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence. Cancer 1993;71:3697–3702.

    CAS  PubMed  Google Scholar 

  • Gurin CC, Federici MG, Kang L, Boyd J. Causes and consequences of MSI in endometrial carcinoma. Cancer Res 1999;59:462–468.

    CAS  PubMed  Google Scholar 

  • Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982;6:93–108.

    CAS  PubMed  Google Scholar 

  • Ichikawa Y, Lemon SJ, Wang S, et al. MSI and expression of MLH1 and MSH2 in normal and malignant endometrial and ovarian epithelium in HNPCC family members. Cancer Genet Cytogenet 1999;112:2–8.

    Article  CAS  PubMed  Google Scholar 

  • Ikeda T, Yoshinaga K, Semba S, Kondo E, Ohmori H, Horii A. Mutational analysis of the CTNNB1 (ß-catenin) gene in human endometrial cancer: frequent mutations at codon 34 that cause nuclear accumulation. Oncology Reports 2000;7:323–326.

    CAS  PubMed  Google Scholar 

  • Inoue M. Current molecular aspects of the carcinogenesis of the uterine endometrium. Int J Gynecol Cancer 2001;11:339–348.

    Article  CAS  PubMed  Google Scholar 

  • International Federation of Gynecology and Obstetrics: classification and staging of malignant tumors in the female pelvis. Int J Gynaecol Obstet 1971;9:172.

    Google Scholar 

  • Ito K, Watanabe K, Nasim S, Sasano H, Saito S, Yajima A. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 1994;54:4667–4670.

    CAS  PubMed  Google Scholar 

  • Jovanovic AS, Boynton KA, Mutter GL. Uteri of women with endometrial carcinoma contain a histopathologic spectrum of monoclonal putative precancers, some with MSI. Cancer Res 1996;56:1917–1921.

    CAS  PubMed  Google Scholar 

  • Kadar N, Homesley HD, Malfetano JH. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol 1992;46:145–149.

    Article  CAS  PubMed  Google Scholar 

  • Kato DT, Ferry J, Goodman A, et al. Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol Oncol 1995;59:384–389.

    Article  CAS  PubMed  Google Scholar 

  • Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744–751.

    Article  PubMed  Google Scholar 

  • Kong D, Suzuki A, Zou TT, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997;17:143–144.

    CAS  PubMed  Google Scholar 

  • Kucera H, Vavra N, Weghaupt K. Benefit of external irradiation in pathologic stage I endometrial carcinoma: a prospective clinical trial of 605 patients who received postoperative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors. Gynecol Oncol 1990;38:99–104.

    Article  CAS  PubMed  Google Scholar 

  • Lambrou NC, Gomez-Marin O, Mirhashemi R, et al. Optimal surgical cytoreduction in patients with stage III and stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol Oncol 2004;93:653–658.

    Article  PubMed  Google Scholar 

  • Lanciano RM, Greven KM. Adjuvant treatment for endometrial cancer: who needs it? Gynecol Oncol 1995;57:135–137.

    Article  CAS  PubMed  Google Scholar 

  • Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990;36:189–191.

    Article  CAS  PubMed  Google Scholar 

  • Levenback C, Burke TW, Silva E, et al. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol 1992;46:317–321.

    CAS  PubMed  Google Scholar 

  • Levine RL, Cargile CB, Blazes MS, van Rees B, Kurman RJ, Ellenson LH. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 1998;58:3254–3258.

    CAS  PubMed  Google Scholar 

  • Mallipeddi P, Kapp DS, Teng N. Long-term survival with adjuvant whole abdominopelvic irradiation for uterine papillary serous carcinoma. Cancer 1993;71:3076–3081.

    CAS  PubMed  Google Scholar 

  • Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001;32:569–577.

    Article  CAS  PubMed  Google Scholar 

  • Mirabelli-Primdahl L, Gryfe R, Kim H, et al. Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 1999;59:3346–3351.

    CAS  PubMed  Google Scholar 

  • Moore DH, Fowler WC Jr, Walton LA, Droegemueller W. Morbidity of lymph node sampling in cancers of the uterine corpus and cervix. Obstet Gynecol 1989;74:180–184.

    CAS  PubMed  Google Scholar 

  • Morrow C, Bundy B, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55–65.

    Article  CAS  PubMed  Google Scholar 

  • Murphy AA, Morales AJ, Kettel LM, Yen SS. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril 1995;64:187–190.

    CAS  PubMed  Google Scholar 

  • Mutter GL, Boynton KA, Faquin WC, et al. Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer. Cancer Res 1996;56:4483–4486.

    CAS  PubMed  Google Scholar 

  • Mutter GL, Wada H, Faquin WC, Enomoto T. K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis. Mol Pathol 1999;52:257–262.

    CAS  PubMed  Google Scholar 

  • Nei H, Saito T, Yamasaki H, Mizumoto H, Ito E, Kudo R. Nuclear localization of ß-catenin in normal and carcinogenic endometrium. Mol Carcinog 1999;25:207–218.

    Article  CAS  PubMed  Google Scholar 

  • Piver MS, Recio FO, Baker TR, Hempling RE. A prospective trial of progesterone therapy for malignant peritoneal cytology in patients with endometrial carcinoma. Gynecol Oncol 1993;47:373–376.

    Google Scholar 

  • Podratz KC, O’Brien PC, Malkasian GD Jr, Decker DG, Jefferies JA, Edmonson JH. Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 1985;66:106–110.

    CAS  PubMed  Google Scholar 

  • Pustilnik T, Burke TW. Adjuvant chemotherapy for high-risk endometrial cancer. Semin Radiat Oncol 2000;10:23–28.

    CAS  PubMed  Google Scholar 

  • Ramondetta L, Burke TW, Levenback C, Bevers M, Bodurka-Bevers D, Gershenson DM. Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol 2001;82:156–161.

    Article  CAS  PubMed  Google Scholar 

  • Reddoch JM, Burke TW, Morris M, et al. Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme. Gynecol Oncol 1995;59:221–225.

    CAS  PubMed  Google Scholar 

  • Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57:4736–4738.

    CAS  PubMed  Google Scholar 

  • Risinger JI, Hayes K, Maxwell GL, et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 1998;4:3005–3010.

    CAS  PubMed  Google Scholar 

  • Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.

    CAS  PubMed  Google Scholar 

  • Schneider CC, Gibb RK, Taylor DD, Wan T, Gercel-Taylor C. Inhibition of endometrial cancer cell lines by mifepristone (RU 486). J Soc Gynecol Investig 1998;5:334–338.

    CAS  PubMed  Google Scholar 

  • Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000;13:295–308.

    Article  CAS  PubMed  Google Scholar 

  • Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268–1274.

    Article  CAS  PubMed  Google Scholar 

  • Silva EG, Jenkins R. Serous carcinoma in endometrial polyps. Mod Pathol 1990;3:120–128.

    CAS  PubMed  Google Scholar 

  • Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol 1997;90:441–447.

    Article  CAS  PubMed  Google Scholar 

  • Staebler A, Lax SF, Ellenson LH. Altered expression of hMLH1 and hMSH2 protein in endometrial carcinomas with MSI. Hum Pathol 2000;31:354–358.

    Article  CAS  PubMed  Google Scholar 

  • Stringer CA, Gershenson DM, Burke TW, Edwards CL, Gordon AN, Wharton JT. Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: a preliminary analysis. Gynecol Oncol 1990;38:305–308.

    Article  CAS  PubMed  Google Scholar 

  • Sun M, Zhu G, Zhou L. Effect of mifepristone on the expression of progesterone receptor messenger RNA and protein in uterine leiomyomata [in Chinese]. Zhonghua Fu Chan Ke Za Zhi 1998;33:227–231.

    CAS  PubMed  Google Scholar 

  • Sutton GP, Blessing JA, DeMars LR, Moore D, Burke TW, Grendys EC. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol 1996;63:25–27.

    Article  CAS  PubMed  Google Scholar 

  • Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935–3940.

    CAS  PubMed  Google Scholar 

  • Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177–185.

    CAS  PubMed  Google Scholar 

  • Tebeu PM, Popowski Y, Verkooijen HM, et al. Positive peritoneal cytology in early-stage endometrial cancer does not influence prognosis. Br J Cancer 2004;91:720–724.

    PubMed  Google Scholar 

  • Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1994;12:1408–1414.

    CAS  PubMed  Google Scholar 

  • Thigpen JT, Blessing JA, Hatch KD, et al. A randomized trial of medroxyprogesterone acetate (MPA) 200 mg versus 1000 mg daily in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study [abstract]. Proc ASCO 1991;10:185.

    Google Scholar 

  • Thigpen JT, Blessing JA, Homesley H, Creasman WT, Sutton G. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 1989;33:68–70.

    Article  CAS  PubMed  Google Scholar 

  • Thigpen JT, Brady MF, Homesley HD, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2004;22:3902–3908.

    Article  CAS  PubMed  Google Scholar 

  • Thigpen JT, Buchsbaum HJ, Mangan C, Blessing JA. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep 1979;63:21–27.

    CAS  PubMed  Google Scholar 

  • Tritz D, Pieretti M, Turner S, Powell D. Loss of heterozygosity in usual and special variant carcinomas of the endometrium. Hum Pathol 1997;28:607–612.

    Article  CAS  PubMed  Google Scholar 

  • Vergote I, Kjorstad K, Abeler V, Kolstad P. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 1989;64:1011–1016.

    CAS  PubMed  Google Scholar 

  • Watson P, Vasen HF, Mecklin JP, Jarvinen H, Lynch HT. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994;96:516–520.

    Article  CAS  PubMed  Google Scholar 

  • Zanotti KM, Belinson JL, Kennedy AW, Webster KD, Markman M. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 1999;74:272–277.

    Article  CAS  PubMed  Google Scholar 

  • Zeng C, Gu M, Huang H. Aclinical control study of the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone [in Chinese]. Zhonghua Fu Chan Ke Za Zhi 1998;33:490–492.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecologic Oncology, USA

    Lois M. Ramondetta MD (Associate Professor) & Thomas W. Burke MD (Professor)

  2. Department of Pathology, USA

    Russell Broaddus MD, PhD (Assistant Professor)

  3. Department of Radiation Oncology, USA

    Anuja Jhingran MD (Associate Professor)

Authors
  1. Lois M. Ramondetta MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas W. Burke MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Russell Broaddus MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anuja Jhingran MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1202, Houston, TX, 77030-4009, USA

    Patricia J. Eifel MD

  2. Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1362, Houston, TX, 77030-4009, USA

    David M. Gershenson MD

  3. Department of Gynecologic Medical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1364, Houston, TX, 77030-4009, USA

    John J. Kavanagh MD

  4. Department of Pathology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 85, Houston, TX, 77030-4009, USA

    Elvio G. Silva MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Ramondetta, L.M., Burke, T.W., Broaddus, R., Jhingran, A. (2006). Treatment of Endometrial Cancer. In: Eifel, P.J., Gershenson, D.M., Kavanagh, J.J., Silva, E.G. (eds) Gynecologic Cancer. M. D. Anderson Cancer Care Series, vol 5. Springer, New York, NY. https://doi.org/10.1007/0-387-28796-5_10

Download citation

  • DOI: https://doi.org/10.1007/0-387-28796-5_10

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-28794-2

  • Online ISBN: 978-0-387-28796-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation